At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib/ II Study of Sorafenib and Pembrolizumab in Advanced Hepatocellular Cancer (HCC)
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Pembrolizumab, and 1 other intervention for Advanced Adult Hepatocellular Carcinoma and 8 related conditions. Completed, enrolled 37 participants across 2 sites.
Detailed Summary
This phase Ib/II trial studies how well sorafenib tosylate and pembrolizumab work in treating patients with liver cancer that has spread to other parts of the body. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving sorafenib tosylate and pembrolizumab may work better in treating patients with liver cancer.
Study Details
Timeline
Interventions
Correlative studies
Given IV
Given PO